Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

A Pilot Randomized Clinical Trial of an Enhanced Pivotal Response Treatment Approach for Young Children with Autism: The PRISM Model.

Authors:
Ty W Vernon Anahita N Holden Amy C Barrett Jessica Bradshaw Jordan A Ko Elizabeth S McGarry Erin J Horowitz Daina M Tagavi Tamsin C German

J Autism Dev Disord 2019 Jun;49(6):2358-2373

University of California Santa Barbara, Santa Barbara, CA, USA.

The symptoms of autism spectrum disorder are conceptualized to alter the quality of parent-children interactions, exposure to social learning exchanges, and ultimately the course of child development. There is evidence that modifying the procedures of Pivotal Response Treatment (PRT) to explicitly target social motivation enhances child engagement and parent-child synchrony in moment-by-moment exchanges. However, it is unclear if these within session improvements ultimately yield favorable developmental outcomes over time. The current investigation presents feasibility, utility, and preliminary efficacy data of a pilot randomized clinical trial (RCT) of a Pivotal Response Intervention for Social Motivation (PRISM) model. Data on participant factors, treatment protocol acceptability, and outcome variance and effect size are highly favorable and support the pursuit of a future, large scale RCT.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10803-019-03909-1DOI Listing
June 2019

Publication Analysis

Top Keywords

pivotal response
12
response treatment
8
social motivation
8
clinical trial
8
pilot randomized
8
randomized clinical
8
exchanges unclear
4
ultimately yield
4
improvements ultimately
4
session improvements
4
unclear session
4
favorable developmental
4
current investigation
4
investigation presents
4
time current
4
outcomes time
4
moment-by-moment exchanges
4
developmental outcomes
4
yield favorable
4
enhances child
4

Keyword Occurance

Similar Publications

Interleukin-35 regulates peripheral T cell activity in patients with Kawasaki disease.

Authors:
Min Sun Haijian Xing

Int Immunopharmacol 2021 Apr 13;96:107642. Epub 2021 Apr 13.

Department of General Internal Medicine, The Children's Hospital Affiliated to Xi'an Jiaotong University (Xi'an Children's Hospital), Xi'an, Shaanxi Province 710003, China. Electronic address:

Interleukin-35 (IL-35) regulates immune cell function in inflammation, infection, cancer, and autoimmune diseases. However, the modulatory activity of IL-35 exerted on T cells is not fully understood in Kawasaki disease. For this purpose, the present study included 28 patients with Kawasaki disease and 16 healthy controls. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

The NLRP3-related inflammasome modulates pain behavior in a rat model of trigeminal neuropathic pain.

Authors:
Xin Sun Liang Cao Jian-Lin Ge Jian-Yun Ge Xue-Feng Yang Bo-Xiang Du Jie Song

Life Sci 2021 Apr 13:119489. Epub 2021 Apr 13.

Department of Anesthesiology, The Second Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu, China. Electronic address:

Aims: Nod-like receptor family pyrin domain containing 3 (NLRP3) may play an important role in neuropathic pain. Treatment for trigeminal neuropathic pain remains a challenge, as common drugs either do not demonstrate beneficial therapeutic effects or induce intolerance in patients.

Main Methods: In a rat model of trigeminal neuropathic pain, pain caused by the malpositioning of dental implants is similar to that experienced by humans. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Circulating pro-gastrin releasing peptide (ProGRP) in patients with medullary thyroid carcinoma.

Authors:
Luca Giovanella Martina Fontana Franco Keller Alfredo Campenni' Luca Ceriani Gaetano Paone

Clin Chem Lab Med 2021 Apr 16. Epub 2021 Apr 16.

Clinic for Nuclear Medicine and Competence Centre for Thyroid Diseases, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.

Objectives: Serum calcitonin (CT) is pivotal in medullary thyroid cancer (MTC) management. Recently, progastrin releasing peptide (ProGRP) has been proposed as a candidate complementary tumor marker of MTC. As current data are sparse our study was undertaken to evaluate the distribution of ProGRP in patients with MTC and its relationship with the tumor burden. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

WRKY transcription factors and plant defense responses: latest discoveries and future prospects.

Authors:
Shabir H Wani Shruti Anand Balwant Singh Abhishek Bohra Rohit Joshi

Plant Cell Rep 2021 Apr 15. Epub 2021 Apr 15.

Division of Biotechnology, CSIR-Institute of Himalayan Bioresource Technology, Palampur, Himachal Pradesh, 176061, India.

Key Message: WRKY transcription factors are among the largest families of transcriptional regulators. In this review, their pivotal role in modulating various signal transduction pathways during biotic and abiotic stresses is discussed. Transcription factors (TFs) are important constituents of plant signaling pathways that define plant responses against biotic and abiotic stimuli besides playing a role in response to internal signals which coordinate different interacting partners during developmental processes. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial.

Authors:
Eriseld Krasniqi Laura Pizzuti Maria Rosaria Valerio Elisabetta Capomolla Claudio Botti Giuseppe Sanguineti Paolo Marchetti Elisabetta Anselmi Silverio Tomao Antonio Giordano Corrado Ficorella Katia Cannita Lorenzo Livi Icro Meattini Maria Mauri Filippo Greco Enzo Maria Veltri Andrea Michelotti Luca Moscetti Francesco Giotta Vito Lorusso Ida Paris Federica Tomao Daniele Santini Giuseppe Tonini Alice Villa Vittorio Gebbia Teresa Gamucci Gennaro Ciliberto Isabella Sperduti Marco Mazzotta Maddalena Barba Patrizia Vici

Int J Med Sci 2021 27;18(10):2245-2250. Epub 2021 Mar 27.

Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Large and consistent evidence supports the use of eribulin mesylate in clinical practice in third or later line treatment of metastatic triple negative breast cancer (mTNBC). Conversely, there is paucity of data on eribulin efficacy in second line treatment. We investigated outcomes of 44 mTNBC patients treated from 2013 through 2019 with second line eribulin mesylate in a multicentre retrospective study involving 14 Italian oncologic centres. Read More

View Article and Full-Text PDF
March 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap